IL2 and systemic lupus erythematosus: He et al. demonstrated in the randomized clinical trial that the group of SLE patients in which low-dose IL2 therapy, along with conventional therapy, was employed for the treatment of SLE offered a higher response rate, which was statistically significant, as compared with the placebo group in which only conventional therapy was used [15].